{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:43:43Z","timestamp":1791150223862,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.rmed.2017.11.009","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T19:47:29Z","timestamp":1511207249000},"page":"6-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Evaluation of the clinical characteristics of everolimus-induced lung injury and determination of associated risk factors"],"prefix":"10.1016","volume":"134","author":[{"given":"Mitsuhiro","family":"Abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2017.11.009_bib1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir. Investig."},{"key":"10.1016\/j.rmed.2017.11.009_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10147-014-0764-5","article-title":"Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma","volume":"20","author":"Nozawa","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2017.11.009_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.11.009_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.11.009_bib5","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1634\/theoncologist.2015-0033","article-title":"Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in waldenstr\u00f6m macroglobulinemia as a paradigm","volume":"20","author":"Nishino","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.rmed.2017.11.009_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature11861","article-title":"mTOR is a key modulator of ageing and age-related disease","volume":"493","author":"Johnson","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.rmed.2017.11.009_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2017.11.009_bib8","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.rmed.2017.11.009_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.rmed.2017.11.009_bib10","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ejca.2012.03.012","article-title":"Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome","volume":"48","author":"Dabydeen","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.rmed.2017.11.009_bib11","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","article-title":"Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib","volume":"24","author":"Ando","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2017.11.009_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature11861","article-title":"mTOR is a key modulator of ageing and age-related disease","volume":"493","author":"Johnson","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.rmed.2017.11.009_bib13","first-page":"25","article-title":"Rechallenge of everolims for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report","volume":"60","author":"Utsunomiya","year":"2014","journal-title":"Hinyokika Kiyo"},{"key":"10.1016\/j.rmed.2017.11.009_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1188\/11.ONF.125-128","article-title":"Noninfectious pneumonitis in a patient with renal cell carcinoma treated with everolimus","volume":"38","author":"Creel","year":"2011","journal-title":"Oncol. Nurs. Forum"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117303839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117303839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:37:08Z","timestamp":1760614628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611117303839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":14,"alternative-id":["S0954611117303839"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2017.11.009","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the clinical characteristics of everolimus-induced lung injury and determination of associated risk factors","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2017.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}